Update on EGFR Antibodies in mCRC

home / insights / update-on-egfr-antibodies-in-mcrc

Recommendations for appropriately managing metastatic colorectal cancer with anti-EGFR therapy based on recent changes to cetuximab dosing.

Trends in Colorectal Cancer Incidence

EP. 1: Trends in Colorectal Cancer Incidence

Zev A. Wainberg, MD, UCLA;Jaffer A. Ajani, MD, MD Anderson Cancer Center
May 25th 2021
Molecular Testing in Metastatic Colorectal Cancer

EP. 2: Molecular Testing in Metastatic Colorectal Cancer

Zev A. Wainberg, MD, UCLA;Jaffer A. Ajani, MD, MD Anderson Cancer Center
May 25th 2021
Next-Generation Sequencing in Metastatic Colorectal Cancer

EP. 3: Next-Generation Sequencing in Metastatic Colorectal Cancer

Zev A. Wainberg, MD, UCLA;Jaffer A. Ajani, MD, MD Anderson Cancer Center
June 1st 2021
Selecting Systemic Therapy for Newly Diagnosed mCRC

EP. 4: Selecting Systemic Therapy for Newly Diagnosed mCRC

Zev A. Wainberg, MD, UCLA;Jaffer A. Ajani, MD, MD Anderson Cancer Center
June 1st 2021
Changes in Cetuximab Dosing Schedule in mCRC

EP. 5: Changes in Cetuximab Dosing Schedule in mCRC

Zev A. Wainberg, MD, UCLA;Jaffer A. Ajani, MD, MD Anderson Cancer Center
June 8th 2021
Sequencing Anti-EGFR Therapy in mCRC

EP. 6: Sequencing Anti-EGFR Therapy in mCRC

Zev A. Wainberg, MD, UCLA;Jaffer A. Ajani, MD, MD Anderson Cancer Center
June 8th 2021
Later-Line Treatment Options for mCRC

EP. 7: Later-Line Treatment Options for mCRC

Zev A. Wainberg, MD, UCLA;Jaffer A. Ajani, MD, MD Anderson Cancer Center
June 15th 2021
EGFR Therapy for mCRC: Dermatologic Toxicity

EP. 8: EGFR Therapy for mCRC: Dermatologic Toxicity

Zev A. Wainberg, MD, UCLA;Jaffer A. Ajani, MD, MD Anderson Cancer Center
June 15th 2021
Future Directions in mCRC

EP. 9: Future Directions in mCRC

Zev A. Wainberg, MD, UCLA;Jaffer A. Ajani, MD, MD Anderson Cancer Center
June 22nd 2021
KRAS G12C Inhibitors in mCRC

EP. 10: KRAS G12C Inhibitors in mCRC

Zev A. Wainberg, MD, UCLA;Jaffer A. Ajani, MD, MD Anderson Cancer Center
June 22nd 2021